



Peer-Reviewed  
Publications Co-Authored  
by STATinMED Research  
**2016-2021**



**STATinMED**

The Authority in Real-World Evidence

- Hutson T, Liu F, Dieyi C, et al. Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in the first-line setting: Results from the IMPACT RCC Real-World Study. *J Managed Care Specialty Pharm*. Forthcoming 2021.
- Huang H, Schmerold L, Dembek C, et al. Healthcare resource utilization, costs and treatment patterns in patients with bipolar disorder treated with lurasidone or cariprazine. *J Med Econ*. 2021. doi: 10.1080/13696998.2021.1890428 [Epub ahead of print].
- Deitelzweig S, Keshishian A, Kang A, et al. Burden of major gastrointestinal bleeding among oral anticoagulant-treated nonvalvular atrial fibrillation patients. *Therap Adv Gastroenterol*. Forthcoming 2021.
- Cohen A, Keshishian A, Lee T, et al. Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: A US claims data analysis. *Thromb Haemost*. 2021;121(3):383-395.
- Bhanegaonkar A, Pandya S, Zheng Y, et al. Real-world outcomes among US Veterans Health Administration patients newly-diagnosed with metastatic renal cell carcinoma and treated with first-line monotherapy. *Adv Ther*. 2021 Apr 17. doi: 10.1007/s12325-021-01657-2. Online ahead of print.
- Huang H, Schmerold L, Dembek C, et al. Healthcare resource utilization, costs and treatment patterns in patients with bipolar disorder treated with lurasidone or cariprazine. *J Med Econ*. 2021;24(1):352-362.
- Rubin DT, Griffith J, Zhang Q, Hepp Z, Keshishian A. The impact of intestinal complications on health care costs among inflammatory bowel disease patients treated with anti-tumor necrosis factor therapies. *Inflamm Bowel Dis*. 2020 Oct 27. [online ahead of print]
- Chen G, Lissoos T, Dieyi C, Null KD. Development and validation of an inflammatory bowel disease (IBD) severity index using US administrative claims data: A retrospective cohort study. *Inflamm Bowel Dis*. 2020 Oct 12. [online ahead of print]
- Guo JD, Hlavacek P, Rosenblatt L, et al. Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare population. *Thromb Res*. 2021;198:163-70.
- Lip G, Keshishian A, Kang A, et al. Oral anticoagulants for non-valvular atrial fibrillation in frail elderly patients: Insights from the ARISTOPHANES study. *J Intern Med*. 2021;289:42-52.
- Bolge SC, Kariburyo F, Yuce H, Fleischhackl R. Predictors and outcomes of hospitalization for influenza: Real world evidence from the United States Medicare population. *Infect Dis Ther*. 2020 [epub ahead of print].
- Obando C, Ding Z, Muser E, et al. Persistence, dose titration, and health care resource utilization among Crohn's disease patients treated with ustekinumab: A real-world analysis in the United States. *Adv Ther*. 2020;37(5):2127-43.
- Huang Q, Borra S, Li J, et al. Time to next treatment, healthcare resource utilization, and costs associated with ibrutinib use among US veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world retrospective analysis. *J Manag Care Spec Pharm*. 2020;26(10):1266-75.

- Sobhy MA, Khoury M, Almahmeed WA, et al. The atrial Fibrillation real World management registry in the Middle East & Africa—Design and rationale. *J Cardiovasc Med.* 2020;21(9):704-10.
- Shah N, Bhor M, Xie L, Paulose J, Yuce H. Medical resource use and costs of treating sickle cell-related vaso-occlusive crisis episodes: A retrospective claims study. *JHEOR.* 2020;7(1):52-60.
- Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and safety of oral anticoagulants among NVAF patients with obesity: Insights from the ARISTOPHANES study. *J Clin Med.* 2020;9(6):1633.
- Amin A, Keshishian A, Trocio J, et al. A real-world observational study of hospitalization and health care costs among non-valvular atrial fibrillation patients prescribed oral anticoagulants in the US Medicare population. *J Manag Care Spec Pharm.* 2020;26(5):639-51.
- Lip GYH, Keshishian AV, Kang AL, et al. Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with diabetes mellitus. *Mayo Clin Proc.* 2020;95(5):929-43.
- Ramaswamy K, Lechpammer S, Mardekian J, et al. Economic outcomes in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate plus prednisone. *Adv Ther.* 2020;37(5):2083-97.
- Patel C, El Khoury A, Huang A, et al. Healthcare resource utilization and costs among patients with schizophrenia switching from oral risperidone/paliperidone to once-monthly paliperidone palmitate: A Veterans Health Administration claims analysis. *Curr Ther Res.* 2020;92:100587.
- Gandhi K, Wei W, Huang A, et al. A real-world study using claims data to evaluate possible failure of opioid treatment regimens among patients with hip and/or knee osteoarthritis in the US. *Clinicoecon Outcomes Res.* 2020;12:285-97.
- Cohen J, Beaubrun A, Bashyal R, et al. Real-world adherence and persistence for newly-prescribed HIV treatment: Single versus multiple tablet regimen comparison among US Medicaid beneficiaries. *AIDS Res Ther.* 2020;17(1):12.
- Sbarigia U, Kariburyo F, Sah J, et al. Evaluating the effect of standard of care treatment on burden of chronic hepatitis B: A retrospective analysis of the United States veterans population. *Adv Ther.* 2020;37(3):1156-72.
- Parasuraman S, Yu J, Paranagama D, et al. Elevated white blood cell levels and thrombotic events in patients with polycythemia vera: A real-world analysis of Veterans Health Administration data. *Clin Lymphoma Myeloma Leuk.* 2020;20(2):63-9.
- Kariburyo F, Xie L, Sah J, et al. Real world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States. *J Med Econ.* 2020;23(1):1-9.
- El Khoury A, Patel C, Huang A, et al. Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among Veterans Health Administration patients with schizophrenia who have had at least one prior hospitalization. *Curr Med Res Opin.* 2019;35(12):2159-68.
- Chowdhury R, Franchino-Elder J, Wang L, et al. Healthcare resource utilization and expenditures among newly diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants. *J Med Econ.* 2019;22(12):1338-50.

- Keshishian A, Xie L, Dembek C, Yuce H. Reduction in hospital readmission rates among Medicare beneficiaries with chronic obstructive pulmonary disease: A real-world outcomes study of nebulized bronchodilators. *Clin Ther.* 2019;41(11):2283-96.
- Shah N, Bhor M, Xie L, et al. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: A retrospective claims-based study. *Health Qual Life Outcomes.* 2019;17(1):155.
- Peacock WF, Coleman CI, Wells P, et al. Clinical and economic outcomes in low-risk pulmonary embolism patients treated with rivaroxaban versus standard of care. *JHEOR.* 2019;6(3):160-73.
- Patel C, El Khoury A, Huang A, et al. Health outcomes among patients diagnosed with schizophrenia in the US Veterans Health Administration population who transitioned from once-monthly to once-every-3-month paliperidone palmitate: An observational retrospective analysis. *Adv Ther.* 2019;36(10):2941-53.
- Parasuraman S, Yu J, Paranagama D, et al. Hematocrit levels and thrombotic events in patients with polycythemia vera: An analysis of veterans health administration data. *Ann Hematol.* 2019;98:2533-9.
- Nazareth T, Kariburyo F, Kirkemo A, et al. Patients with idiopathic membranous nephropathy: A real-world clinical and economic analysis of U.S. claims data. *J Manag Care Spec Pharm.* 2019;25(9):1011-20.
- Amin A, Keshishian A, Dina O, et al. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS Medicare population. *J Thromb Thrombolysis.* 2019;48(2):240-9.
- Deitelzweig S, Keshishian A, Li X, et al. Comparisons between oral anticoagulants among older nonvalvular atrial fibrillation patients. *J Am Geriatr Soc.* 2019;67(8):1662-71.
- Shah N, Bhor M, Xie L, Paulose J, Yuce H. Sickle cell disease complications: Prevalence and resource utilization. *PLoS One.* 2019;14(7):e0214355.
- Wells P, Peacock WF, Fermann GJ, et al. The value of sPESI for risk stratification in patients with pulmonary embolism. *J Thromb Thrombolysis.* 2019;48(1):149-57.
- Ng-Mak D, Messali A, Huang A, et al. Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics. *Am J Manag Care.* 2019;25(14 Suppl):S279-S286.
- Zhou FL, Nicholls C, Xie L, et al. Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real-world setting. *Endocrinol Diabetes Metab.* 2019;2(3):e00073.
- Gupta K, Trocio J, Keshishian A, et al. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of Defense population. *BMC Cardiovasc Disord.* 2019;19(1):142.
- Shah N, Bhor M, Xie L, et al. Evaluation of vaso-occlusive crises in United States sickle cell disease patients: A retrospective claims-based study. *JHEOR.* 2019;6(3):106-117.
- Pandya S, Baser O, Wan G, et al. The burden of hypoxic respiratory failure in preterm and term/near-term infants in the United States 2011-2015. *JHEOR.* 2019;6(3):130-41.
- Wang L, Baser O, Wells P, et al. Predictors of hospital length of stay among patients with low-risk pulmonary embolism. *JHEOR.* 2019;6(2):84-94.

- Amin A, Garcia Reeves AB, Li X, et al. Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure. *PLOS One*. 2019;14(3):e0213614.
- Lim J, Samuelsen C, Golembesky A, et al. Duration of treatment for patients prescribed first-line afatinib/erlotinib for EGFR mutation-positive NSCLC in the US. *Future Oncol*. 2019;15(13):1493-504.
- McNamara MA, George DJ, Ramaswamy K, et al. Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. *J Clin Oncol*. 2019;37(7):212.
- Zhao Q, Wang L, Kurlansky PA, et al. Cardiovascular outcomes among elderly patients with heart failure and coronary artery disease and without atrial fibrillation: A retrospective cohort study. *BMC Cardiovasc Disord*. 2019;19(1):19.
- Sietsema D, Araujo A, Wang L, et al. The effectiveness of a private orthopedic practice-based osteoporosis management program to reduce the risk of subsequent fractures. *J Bone Joint Surgery*. 2018;100(21):1819-28.
- Gupta K, Trocio J, Keshishian A, et al. Real-world comparative effectiveness, safety, and health care costs of oral anticoagulants in non-valvular atrial fibrillation patients in the United States Department of Defense population. *J Manag Care Spec Pharm*. 2018;24(11):1116-1127.
- Shah A, Xie L, Kariburyo F, et al. Treatment patterns, healthcare resource utilization and costs among schizophrenia patients treated with long-acting injectable versus oral antipsychotics. *Adv Ther*. 2018;35(11):1994-2014.
- Yazici Y, Xie L, Ogbomo A, et al. Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab. *Biologics: Targets Ther*. 2018;8:127-134.
- Yazici Y, Xie L, Ogbomo A, et al. A descriptive analysis of real-world treatment patterns of innovator (Remicade®) and biosimilar infliximab in an infliximab-naïve Turkish population. *Biologics: Targets Ther*. 2018;12:97-106.
- Huang A, Amos TB, Joshi K, et al. Understanding healthcare burden and treatment patterns among young adults with schizophrenia. *J Med Econ*. 2018;21(10):1026-35.
- Keshishian A, Greenberg SA, Agashivala N, Baser O, Johnson K. Health care costs and comorbidities for patients with inclusion body myositis. *Curr Med Res Opin*. 2018;34(9):1679-85.
- Lopes RD, Steffel J, Di Fusco M, et al. Effectiveness/safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and concomitant coronary/peripheral artery disease. *Am J Med*. 2018;131(9):1075-1085.e4.
- Shrestha S, Baser O, Kwong WJ. Effect of renal function on dosing of non-vitamin K-antagonist direct oral anticoagulants among patients with non-valvular atrial fibrillation. *Ann Pharmacother*. 2018;52(2):147-153.
- Lee S, Xie L, Wang Y, Vaidya N, Baser O. Evaluating the impact of treatment persistence on the economic burden of moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population. *J Manag Care Spec Pharm*. 2018;24(7):654-63.

- Huntington S, Keshishian A, McGuire M, Xie L, Baser O. Costs of relapsed diffuse large B-cell lymphoma among Medicare patients. *Leuk Lymphoma*. 2018;59(12):2880-7.
- Kariburyo F, Wang Y, Cheng IE, et al. Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study. *BMC Urol*. 2018;18(1):55.
- Sonpavde G, Huang A, Wang L, et al. Taxane chemotherapy versus anti-androgen agents as first-line therapy for metastatic castration-resistant prostate cancer. *BJU Int*. 2018;121(6):871-9.
- Lee S, Xie L, Wang Y, et al. Comorbidity and economic burden among moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population. *J Med Econ*. 2018;21(6):564-70.
- Lopes RD, Steffel J, Di Fusco M, et al. Effectiveness and safety of oral anticoagulants in adults with non-valvular atrial fibrillation and concomitant coronary/peripheral artery disease. *Am J Med*. 2018;131(9):1075-85.e4.
- Parasuraman S, Yu J, Paragama D, et al. Cytoreductive treatment patterns among US veterans with polycythemia vera. *BMC Cancer*. 2018;(18):528.
- Tang WY, Grothe D, Keshishian A, et al. Pharmacoeconomic and associated cost savings among women who were prescribed systemic conjugated estrogens therapy compared to those without menopausal therapy. *Menopause*. 2018;25(5):493-9.
- Zhou FL, Xie L, Pan C, et al. Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiating basal insulin. *Diabetes Obes Metab*. 2018;20(5):1298-301.
- Steward R, Carney P, Law A, et al. Long-term outcomes after elective sterilization procedures—a comparative retrospective cohort study of Medicaid patients. *Contraception*. 2018;97(5):428-33.
- Khandker RK, Black CM, Xie L, et al. Analysis of episodes of care in Medicare beneficiaries diagnosed with Alzheimer's disease. *J Am Geriatr Soc*. 2018;66(5):864-70.
- Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients: The ARISTOPHANES study. *Stroke*. 2018;49(12):2933-2944.
- Li X, Keshishian A, Hamilton M, et al. Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: comparative effectiveness and safety evaluated using a propensity-score-matched approach. *PLOS One*. 2018;13(1):e0191722.
- Black CM, Fillit H, Xie L, et al. Economic burden, mortality and institutionalization in patients newly diagnosed with Alzheimer's disease. *J Alzheimers Dis*. 2018;61(1):185-93.
- Fu RH, Toyoda Y, Li L, et al. Smoking and postoperative complications in plastic and general surgical procedures: A propensity-score matched analysis of 294,903 patients from the NSQIP database from 2005 to 2014. *Plastic Reconstruct Surg*. 2018;141(1):226-236.
- Nguyen C, Xie L, Alley S, et al. Epidemiology and economic burden of serotonin syndrome with concomitant use of serotonergic agents: A retrospective study utilizing two large US claims databases. *Prim Care Companion CNS Disord*. 2017;19(6):17m02200.

- Brekke L, Buysman E, Grabner M, Ke X, Xie L, Baser O, Wei W. The use of decomposition methods in real-world treatment benefits evaluation for patients with type 2 diabetes initiating different injectable therapies: Findings from the INITIATOR study. *Value Health*. 2017;20:1252-59.
- Amin A, Keshishian A, Vo L, et al. Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for nonvalvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan. *J Med Econ*. 2018;21(3):244-53.
- Al-Mazrou AM, Baser O, Kiran RP. Failure of efforts to contain costs of care after colorectal procedures: Nationwide trends in length of stay, costs and post-acute care utilization. *Am J Surg*. 2017;214(5):804-10.
- Keshishian A, Boytsov N, Burge R, et al. Examining the impact of medication adherence on risk of subsequent fracture among women with a fragility fracture in the US Medicare population. *J Manag Care Pharm*. 2017;23(11):1178-90.
- Wang L, Baser O, Wells P, et al. Benefit of early discharge among patients with low-risk pulmonary embolism. *PLoS One*. 2017;12(10):e0185022.
- Amin A, Keshishian A, Trocio J, et al. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States Medicare population. *Curr Med Res Opin*. 2017;33(9):1595-1604.
- Dalal MR, Kazemi M, Ye F, Xie L. Hypoglycemia after initiation of basal insulin in patients with type 2 diabetes in the United States: Implications for treatment discontinuation and healthcare costs and utilization. *Adv Ther*. 2017;34(9):2083-92.
- Kohn CG, Weeda ER, Kumar N, et al. External validation of a claims-based and clinical approach for predicting post-pulmonary embolism outcomes among United States veterans. *Intern Emerg Med*. 2017;12(5):613-619.
- Wei W, Knapp K, Wang L, et al. Treatment persistence and clinical outcomes of tumor necrosis factor inhibitor cycling or switching to a new mechanism of action therapy: Real-world observational study of rheumatoid arthritis patients in the United States with prior tumor necrosis factor inhibitor therapy. *Adv Ther*. 2017;34(8):1936-52.
- Shrestha S, Miao R, Wang L, et al. Burden of atopic dermatitis in the United States: analysis of healthcare claims data in the Commercial, Medicare, and Medi-Cal Databases. *Adv Ther*. 2017;34:1989-2006.
- Keshishian A, Boytsov N, Burge R, et al. Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population. *Osteoporos Int*. 2017;28(8):2485-94.
- Wang L, Baser O, Wells P, et al. Overall effectiveness of rivaroxaban among pulmonary embolism patients. *Clin Ther*. 2017;39(7):1426-36.e2.
- Kariburyo F, Wang Y, Cheng IN, et al. Healthcare costs among men with favorable risk prostate cancer managed with observation strategies versus immediate treatment in an integrated health care system. *J Med Econ*. 2017;20(8):825-31.
- Kariburyo F, Xie L, Teeple A, et al. Predicting pre-emptive discussions of biologic treatment: Results from an openness and preference survey of inflammatory bowel disease patients and their prescribers. *Adv Ther*. 2017;34(6):1398-1410.

- Knight T, Bond C, Popelar B, et al. Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab. *Clinicoecon Outcomes Res.* 2017;9:271-279.
- Bent-Enakhil N, Coste F, Xie L, et al. A real-world analysis of treatment patterns for cholinesterase inhibitors and memantine among newly-diagnosed Alzheimer's disease patients. *Neurol Ther.* 2017;6(1):131-144.
- Pesa JA, Doshi D, Wang L, et al. Health care resource utilization and costs of California-Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment. *Curr Med Res Opin.* 2017;33(4):723-31.
- Li X, Deitelzweig S, Keshishian A, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice: A propensity-matched analysis of 76,940 patients. *Thromb Haemost.* 2017;117(6):1072-82.
- Wei W, Buysman E, Grabner M, et al. A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 diabetes initiating injectable therapies. *Diabetes Obes Metab.* 2017;19(3):375-86.
- Nelson WW, Milentijevic D, Wang L, et al. Patterns of international normalized ratio values among new warfarin patients with non-valvular atrial fibrillation. *Blood Coag Fibrinolysis.* 2016;27(8):899-906.
- Xie L, Liu X, Phatak H, et al. Warfarin discontinuation in patients with unprovoked venous thromboembolism: A large US insurance database analysis. *Am J Ther.* 2016;23(6):e1744-53.
- Cai J, Wang Y, Baser O, Xie L, Chow W. Comparative persistence and adherence with newer antihyperglycemic agents to treat patients with type 2 diabetes in the United States. *J Med Econ.* 2016;19(12):1175-86.
- Yu H, Baser O, Wang L. Burden of Clostridium difficile-associated disease among patients residing in nursing homes: a population-based cohort study. *BMC Geriatr.* 2016;16:193.
- Shorr AF, Zilberberg MD, Wang L, Baser O, Yu H. Mortality and costs in Clostridium difficile infection disease among the elderly in the United States. *Infect Control Hosp Epidemiol.* 2016;37(11):1331-6.
- Lip GYH, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin: A propensity score matched analysis. *Thromb Haemost.* 2016;116(5):975-86.
- Xie L, Vo L, Keshishian A, et al. Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: an early view. *J Med Econ.* 2016;19(8):769-76.
- Zilberberg MD, Shorr AF, Wang L, Baser O, Yu H. Development and validation of a risk score for clostridium difficile infection in Medicare beneficiaries: A population-based cohort study. *J Am Geriatr Soc.* 2016;64(8):1690-5.
- Quek RGW, Fox KM, Wang L, et al. A US claims-based analysis of real-world lipid-lowering treatment patterns among patients with high cardiovascular disease risk or a previous coronary event. *Am J Cardiol.* 2016;117(4):495-500.



- Fox K, Wang L, Gandra SR, et al. Clinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: A retrospective cohort study. *BMC Cardiovasc Disord.* 2016;16:13.
- Keshishian A, Wang Y, Xie L, Baser O. The economic impact of symptomatic menopause among low-socioeconomic women in the United States. *Expert Rev Pharmacoecon Outcomes Res.* 2016;16(2):305-13.
- Baser O, Wang L, Maguire J. Creating national weights for a patient-level longitudinal database. *JHEOR.* 2016;4(1):80-9.